Skip to content

Noninvasive brain stimulation for attention deficits after traumatic brain injury

Brain stimulation, an innovative approach for the treatment of attention deficits after traumatic brain injury during the inpatient phase of rehabilitation: a feasibility study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN55243064
Enrollment
5
Registered
2020-10-15
Start date
2018-09-01
Completion date
Unknown
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficits after traumatic brain injury Injury, Occupational Diseases, Poisoning

Interventions

Participants will receive the tDCS protocol, which consists of 20 minutes tDCS active stimulation three times a week for 3 weeks for a total of nine sessions. The tDCS will be applied by experienced r
Soterix Medical, New York, NY, USA). Current delivery will be monitored throughout the testing. Participants will undergo 20-minute sessions of tDCS at an intensity of 2 mA and a current density of 0,

Sponsors

Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Current hospitalization 2. Age 18 years old or more 3. Diagnosis of mild complicated, moderate or severe TBI 4. Attentional impairment as per qualitative clinical assessment 5. French or English speaking 6. Tolerance to 45 to 60 minutes neuropsychology evaluation 7. Capacity to consent in accordance with the Nova Scotia Hospitals Act

Exclusion criteria

Exclusion criteria: 1. History of neurological disease not resulting from the current TBI (e.g., stroke, multiple sclerosis, neurodegenerative disorders) 2. Psychiatric illness (e.g., depression, schizophrenia, anxiety disorders) 3. Aphasia and compromises in understanding instructions 4. Significant deafness or blindness 5. Contraindication to tDCS (e.g., seizure, extensive cranial vault lesion, pregnancy or breastfeeding, pacemaker, cochlear implants or cerebral metal implanted device or clip) 6. Scar or skull deformity at the site of electrodes placement 7. Epileptogenic medication 8. Penetrating TBI

Design outcomes

Primary

MeasureTime frame
Tolerance, adverse effects and safety measured using a customized questionnaire adapted from those provided by Brunoni et al. at the end of each stimulation

Secondary

MeasureTime frame
1. Selective attention measured using the Test of Everyday Attention and the Stroop from the Delis-Kaplan Executive Function System at baseline and after the last stimulation session 2. Sustained and selective attention measured using the Ruff 2 &7 Selective Attention Test at baseline and after the last stimulation session 3. Visual sustained attention, vigilance, impulsivity and inattentiveness measured using the Conners Continuous Performance Test 3rd Edition at baseline and after the last stimulation session 4. Visual sustained attention, vigilance, impulsivity and inattentiveness measured using the Conners Continuous Performance Test 3rd Edition at baseline and after the last stimulation session 5. Working memory measured using the Digit Span subtest from the Wechsler adult intelligence scale–Fourth Edition (WAIS-IV) at baseline and after the last stimulation session 6. Processing speed measured using the Coding subtests from the WAIS-IV Edition at baseline and after the last stimulation session 7. Ability to analyze and synthesize abstract visual stimuli measured using the Block Design subtest from the WAIS-IV at baseline and after the last stimulation session

Countries

Canada

Contacts

Public ContactEve Boissonnault
eve.boissonnault@umontreal.ca+1 (0)514 295 3395

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 22, 2026